I will also highlight the continued strong performance of Roxadustat in China and the potential for Roxadustat development for the treatment of anemia due to lower-risk myelodysplastic syndrome. Then ...

Its portfolio includes roxadustat, approved for treating anemia in chronic kidney disease patients across multiple regions, and FG-3246, an innovative antibody-drug conjugate targeting CD46 in ...